Federico Grossi, MD, PhD

Trials

Studies that name Federico Grossi, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:51 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT03593200 · A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH

  Apellis Pharmaceuticals, Inc. · completed · PNH · study director
• Ph1/Ph2
  NCT03465709 · Pegcetacoplan (APL-2) in Neovascular AMD

  Apellis Pharmaceuticals, Inc. · terminated · Neovascular Age-related Macular Degeneration · study director
• Ph1
  NCT02588833 · Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.

  Apellis Pharmaceuticals, Inc. · completed · Paroxysmal Nocturnal Hemoglobinuria · study director
• Ph2
  NCT02503332 · Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy

  Apellis Pharmaceuticals, Inc. · completed · Geographic Atrophy
• Ph1
  NCT02461771 · Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

  Apellis Pharmaceuticals, Inc. · completed · Neovascular Age-Related Macular Degeneration
• Ph1
  NCT02264639 · A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH

  Apellis Pharmaceuticals, Inc. · completed · Paroxysmal Nocturnal Hemoglobinuria (PNH) · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.